Fermish Clinical Technologies Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 19.62%
(FY 2023)
- Profit -7.97%
(FY 2023)
- Ebitda -3.28%
(FY 2023)
- Net Worth 22.87%
(FY 2023)
- Total Assets 17.45%
(FY 2023)
About Fermish Clinical Technologies
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Khalid Khan and Mumtaz Khan serve as directors at the Company.
- CIN/LLPIN
U24232DL2005PTC132250
- Company No.
132250
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Fermish Clinical Technologies Private Limited offer?
Fermish Clinical Technologies Private Limited offers a wide range of products and services, including Company Law & Labour Law Consultants, Statutory Compliance Services, Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Fermish Clinical Technologies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Khalid Khan  | Director | 19-Jan-2005 | Current |
| Mumtaz Khan | Director | 19-Jan-2005 | Current |
Financial Performance of Fermish Clinical Technologies.
Fermish Clinical Technologies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.62% increase. The company also saw a slight decrease in profitability, with a 7.97% decrease in profit. The company's net worth Soared by an impressive increase of 22.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fermish Clinical Technologies?
In 2023, Fermish Clinical Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fermish Clinical Technologies?
Unlock and access historical data on people associated with Fermish Clinical Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fermish Clinical Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fermish Clinical Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
